Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Wav
Post# of 420
(Total Views: 193)
Posted On: 05/25/2022 4:13:24 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Waves in the Growing Antiviral Drug Space with its DehydraTECH Technology
- Lexaria Bioscience Corp., through its patented DehydraTECH technology, is improving the way many drugs enter the bloodstream
- In June 2021, the company proved that an antiviral drug enhanced with its technology was effective at inhibiting the COVID-19/SARS-CoV-2 virus
- With the global antiviral market projected to hit $66.7 billion by 2025, Lexaria plans to capitalize on this growth by pushing its DehydraTECH technology and exploring multiple avenues of related application
Today, it is estimated that infectious diseases account for a quarter to one-third of mortality globally. This has mainly been attributed to increased travel, globalization, populated cities, urbanization, and changes in human behavior, among other reasons. These mortalities occur despite significant advancements and developments in the pharmaceutical industry, as has been well evidenced by recent virus outbreaks, including Covid-19, SARS, and Swine Flu, among others (https://nnw.fm/LghXT ).
The current concerns surrounding virus-related and other diseases encourage the medical industry to revisit its approach to treating such conditions. A viable solution that has been identified is the improvement of the bioavailability of pharmaceuticals, ultimately increasing their efficiency in the body. One company helping to push this solution forward is Lexaria Bioscience (NASDAQ: LEXX).
Regarded as a global innovator in drug delivery platforms for its patented DehydraTECH(TM) technology, Lexaria is at the forefront of improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. The technology achieves this by increasing the body’s ability to absorb fat-soluble APIs.
From an economic standpoint, Lexaria’s DehydraTECH allows for less expensive, fast-acting, and more effective oral drug delivery, allowing for the potential of better and faster treatment of various ailments and conditions. So far, the company has filed for patent protection for the delivery of antiviral drugs, testosterone, cannabinoids, nicotine, NSAIDs, PDE5 inhibitors, and more, with additional classes of APIs under investigation.
In June 2021, following the VIRAL-C21-3 clinical study, Lexaria announced that remdesivir and ebastine processed with DehydraTECH proved effective at inhibiting the COVID-19/SARS-CoV-2 virus. This study was the highlight of the company’s 2021 antiviral drug R&D program and a demonstration of DehydraTECH’s potential, not just for SARS-CoV-2 but also for HIV and other infectious disease-causing viruses (https://nnw.fm/tdcLX ).
The antiviral drug market was valued at $52.1 billion in 2021. It is projected that by 2025, this industry will be valued at over $66.7 billion, mainly driven by a significant increase in the rate of viral infections. Lexaria recognizes this opportunity and is working towards being at the forefront of satisfying the need in this market.
With its DehydraTECH technology, Lexaria is confident it could offer solutions that could benefit millions of people, from those dealing with infectious diseases to those living with hypertension.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience Corp., through its patented DehydraTECH technology, is improving the way many drugs enter the bloodstream
- In June 2021, the company proved that an antiviral drug enhanced with its technology was effective at inhibiting the COVID-19/SARS-CoV-2 virus
- With the global antiviral market projected to hit $66.7 billion by 2025, Lexaria plans to capitalize on this growth by pushing its DehydraTECH technology and exploring multiple avenues of related application
Today, it is estimated that infectious diseases account for a quarter to one-third of mortality globally. This has mainly been attributed to increased travel, globalization, populated cities, urbanization, and changes in human behavior, among other reasons. These mortalities occur despite significant advancements and developments in the pharmaceutical industry, as has been well evidenced by recent virus outbreaks, including Covid-19, SARS, and Swine Flu, among others (https://nnw.fm/LghXT ).
The current concerns surrounding virus-related and other diseases encourage the medical industry to revisit its approach to treating such conditions. A viable solution that has been identified is the improvement of the bioavailability of pharmaceuticals, ultimately increasing their efficiency in the body. One company helping to push this solution forward is Lexaria Bioscience (NASDAQ: LEXX).
Regarded as a global innovator in drug delivery platforms for its patented DehydraTECH(TM) technology, Lexaria is at the forefront of improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. The technology achieves this by increasing the body’s ability to absorb fat-soluble APIs.
From an economic standpoint, Lexaria’s DehydraTECH allows for less expensive, fast-acting, and more effective oral drug delivery, allowing for the potential of better and faster treatment of various ailments and conditions. So far, the company has filed for patent protection for the delivery of antiviral drugs, testosterone, cannabinoids, nicotine, NSAIDs, PDE5 inhibitors, and more, with additional classes of APIs under investigation.
In June 2021, following the VIRAL-C21-3 clinical study, Lexaria announced that remdesivir and ebastine processed with DehydraTECH proved effective at inhibiting the COVID-19/SARS-CoV-2 virus. This study was the highlight of the company’s 2021 antiviral drug R&D program and a demonstration of DehydraTECH’s potential, not just for SARS-CoV-2 but also for HIV and other infectious disease-causing viruses (https://nnw.fm/tdcLX ).
The antiviral drug market was valued at $52.1 billion in 2021. It is projected that by 2025, this industry will be valued at over $66.7 billion, mainly driven by a significant increase in the rate of viral infections. Lexaria recognizes this opportunity and is working towards being at the forefront of satisfying the need in this market.
With its DehydraTECH technology, Lexaria is confident it could offer solutions that could benefit millions of people, from those dealing with infectious diseases to those living with hypertension.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼